Journal article
Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy
V Madhavi, FE Ana-Sosa-Batiz, S Jegaskanda, RJ Center, WR Winnall, MS Parsons, J Ananworanich, DA Cooper, AD Kelleher, D Hsu, S Pett, I Stratov, M Kramski, SJ Kent
Journal of Infectious Diseases | Published : 2015
Abstract
Background Combination antiretroviral therapy (cART) effectively controls human immunodeficiency virus (HIV) infection but does not eliminate HIV, and lifelong treatment is therefore required. HIV-specific cytotoxic T lymphocyte (CTL) responses decline following cART initiation. Alterations in other HIV-specific immune responses that may assist in eliminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear. Methods A cohort of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count, 188 cells/μL; mean viral load, 5.4 log10 copies/mL) was followed for 96 weeks after initiating cART. AD..
View full abstractRelated Projects (1)
Grants
Awarded by Australian National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the Australian National Health and Medical Research Council (award 510448).